Picture1.jpg
ONCOTELIC THERAPEUTICS, INC. ANNOUNCES PRESENTATION AT AYURVEDIC PERSPECTIVES ON COVID-19.
31 mars 2021 07h00 HE | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC) (f/k/a Mateon Therapeutics, Inc.) announced today that the Chopra...
MateonLogo.jpg
MATEON THERAPEUTICS AND WINDLAS BIOTECH PUBLISH PULMOHEAL™ CLINICAL DATA AGAINST COVID-19 IN PEER-REVIEWED JOURNALS
01 mars 2021 07h00 HE | Mateon Therapeutics, Inc.
AGOURA HILLS, California, March 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and...
Basic Photo
MATEON’S C001- A GLOBAL PHASE 2 STUDY FOR OT-101 AGAINST COVID-19- RECEIVED CLEARANCE FOR PATIENT ENROLLMENT
04 nov. 2020 07h00 HE | Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today the receipt of approval from Instituto Nacional de Salud...
Mateon Therapeutics
MATEON ADVISOR DR. SUHAS KSHIRSAGAR WILL PRESENT AT DELHI UNIVERSITY ON ARTISHIELD™ FOR IMPROVING SYMPTOMS FOR COVID-19
23 oct. 2020 07h00 HE | Mateon Therapeutics, Inc.
Dr. Kshirsagar will speak on ARTIShield™ at Delhi University on Oct 28, 2020 in his talk titled “Ayurveda concepts of Pandemic and Immunity”Dr. Kshirsagar is advisor to Mateon on its Ayurvedic product...
MateonLogo.jpg
MATEON TO PARTICIPATE IN BIO INVESTOR FORUM DIGITAL
12 oct. 2020 08h00 HE | Mateon Therapeutics, Inc.
AGOURA HILLS, California, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, today announced...
MateonLogo.jpg
Mateon Therapeutics to fund observational studies of Artemisinin in developing countries.
13 juil. 2020 07h00 HE | Mateon Therapeutics, Inc.
Agoura Hills, California, July 13, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today that it will fund observational studies for...